NCT04727580View on ClinicalTrials.gov

HSK7653 in Chinese Patients with Impaired Glucose Tolerance

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

June 12, 2022

Study Completion Date

June 29, 2022

Conditions
Impaired Glucose Tolerance
Interventions
DRUG

HSK7653 10mg Q2W

HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12

DRUG

HSK7653 25mg Q2W

HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

DRUG

Placebo

Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

Trial Locations (1)

100028

Emergency General Hospital, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT04727580 - HSK7653 in Chinese Patients with Impaired Glucose Tolerance | Biotech Hunter | Biotech Hunter